Temelimab versus placebo in patients with post-COVID condition

Thumbnail Image

Files

Temelimab_versus_placebo.pdf (1.92 MB)
Identifiers
URI: https://hdl.handle.net/11268/17301
DOI: 10.1016/j.bbi.2026.106892

Publication date

2026

Authors

Nehme, Mayssam
Hund Georgiadis, Margret
Corral Beamonte, Esther Del
Bridevaux, Pierre Olivier
Hoepner, Robert

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

SDG

goal-3
goal-9
goal-17

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

More than 400 million individuals are estimated to have been affected by post-COVID condition or long COVID. This condition can lead to significantly decreased quality of life and increased individual and societal costs. Temelimab, a monoclonal IgG4 backbone antibody targeting HERV-W ENV, may be a potential treatment for post-COVID. In adults with persistent symptoms due to post-COVID condition, the use of Temelimab did not show improvement in fatigue compared to placebo.

Description

UNESCO Subjects

Ciencias médicas
Inmunología
Farmacología

Keywords

Bibliographic reference

Nehme, M., Hund-Georgiadis, M., Corral Beamonte, E. D., Bridevaux, P.-O., Hoepner, R., Penner, I.-K., Strobel, J., Fretz, G., Rovira, M. B., Puchades, F., Landi, F., Vasco, P. G., Guaraldi, G., Cordero, F. M., Sebastianelli, L., Sarmati, L., Berthuy, N., Wojcik, J., Keddad, K., … Guessous, I. (2026). Temelimab versus placebo in patients with post-COVID condition. Brain, Behavior, and Immunity, 138, 106892. https://doi.org/10.1016/j.bbi.2026.106892
Editor's version
https://doi.org/10.1016/j.bbi.2026.106892

Type of document

journal article

Collections

Área de Ciencias de la Salud
Attribution 4.0 International

La licencia de este ítem se describe como Attribution 4.0 International